Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine

References

• Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366(9483):397–408. Jul 30–Aug 5. PubMed PMID: 16054941.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636–2644. PubMed PMID: 12860938.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627–1639. PubMed PMID: 26412456; PubMed Central PMCID: PMCPMC5705936.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 Jul 9;373(2):123–135. PubMed PMID: 26028407; PubMed Central PMCID: PMCPMC4681400.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015 May 21;372(21):2006–2017. PubMed PMID: 25891304; PubMed Central PMCID: PMCPMC5744258.
   PubMed Web of Science ®Google Scholar
• Inai K. Pathology of mesothelioma. Environ Health Prev Med. 2008 Mar;13(2):60–64. PubMed PMID: 19568882; PubMed Central PMCID: PMCPMC2698271
   PubMedGoogle Scholar
• Bolukbas S, Manegold C, Eberlein M, et al. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer. 2011 Jan;71(1):75–81. PubMed PMID: 19765853.
   PubMed Web of Science ®Google Scholar
• de Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009 Mar 20;27(9):1413–1418. PubMed PMID: 19224855.
   PubMed Web of Science ®Google Scholar
• Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009 Jun 20;27(18):3007–3013. PubMed PMID: 19364962; PubMed Central PMCID: PMCPMC3646305.
   PubMed Web of Science ®Google Scholar
• Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999 Jan; 117(1):54–63; discussion 63–5. PubMed PMID: 9869758.
   PubMed Web of Science ®Google Scholar
• Verma V, Ahern CA, Berlind CG, et al. Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection. J Thorac Cardiovasc Surg. 2018 Oct 22. PubMed PMID: 30454981. DOI:10.1016/j.jtcvs.2018.10.039.
   Web of Science ®Google Scholar
• Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 2;387(10026):1405–1414. PubMed PMID: 26719230.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Ardito R, Conti B, et al. A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma. Respir Med. 2018 Aug;141:72–80. PubMed PMID: 30053976.
   PubMed Web of Science ®Google Scholar
• Anraku M, Cunningham KS, Yun Z, et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2008 Apr;135(4):823–829. PubMed PMID: 18374762.
   PubMed Web of Science ®Google Scholar
• Burt BM, Rodig SJ, Tilleman TR, et al. Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer. 2011 Nov 15;117(22):5234–5244. PubMed PMID: 21523763.
   PubMed Web of Science ®Google Scholar
• Hegmans JP, Hemmes A, Hammad H, et al. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J. 2006 Jun;27(6):1086–1095. PubMed PMID: 16540497.
   PubMed Web of Science ®Google Scholar
• Marcq E, Siozopoulou V, De Waele J, et al. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. Oncoimmunology. 2017;6(1):e1261241. PubMed PMID: 28197385; PubMed Central PMCID: PMCPMC5283621.
   PubMed Web of Science ®Google Scholar
• Yamada N, Oizumi S, Kikuchi E, et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 2010 Oct;59(10):1543–1549. PubMed PMID: 20567822.
   PubMed Web of Science ®Google Scholar
• Mudhar HS, Fisher PM, Wallace WAH. No relationship between tumour infiltrating lymphocytes and overall survival is seen in malignant mesothelioma of the pleura. Eur J Surg Oncol. 2002 Aug;28(5):564–565. PubMed PMID: WOS:000177939500018; English
   PubMedGoogle Scholar
• Burt BM, Bader A, Winter D, et al. Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. Clin Cancer Res. 2012 Mar 15;18(6):1568–1577. PubMed PMID: 22261806; English.
   PubMed Web of Science ®Google Scholar
• Cornelissen R, Lievense LA, Maat AP, et al. Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma. PLoS One. 2014 Sep 5;9(9):e106742. PubMed PMID: 25192022; PubMed Central PMCID: PMCPMC4156398. English.
   PubMed Web of Science ®Google Scholar
• Cornelissen R, Lievense LA, Robertus JL, et al. Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma. Lung Cancer. 2015 Jun;88(3):332–337. PubMed PMID: 25843042; English.
   PubMed Web of Science ®Google Scholar
• Schurch CM, Forster S, Bruhl F, et al. The “don’t eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma. Oncoimmunology. 2017;7(1):e1373235. PubMed PMID: 29296529; PubMed Central PMCID: PMCPMC5739575. English.
   PubMed Web of Science ®Google Scholar
• Robinson BW, Robinson C, Lake RA. Localised spontaneous regression in mesothelioma – possible immunological mechanism. Lung Cancer. 2001 May;32(2):197–201. PubMed PMID: 11325491
   PubMed Web of Science ®Google Scholar
• Robinson C, Callow M, Stevenson S, et al. Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. Am J Respir Cell Mol Biol. 2000 May;22(5):550–556. PubMed PMID: 10783126.
   PubMed Web of Science ®Google Scholar
• Webster I, Cochrane JW, Burkhardt KR. Immunotherapy with BCG vaccine in 30 cases of mesothelioma. S Afr Med J. 1982 Feb 20;61(8):277–278. PubMed PMID: 7058460; English.
   PubMed Web of Science ®Google Scholar
• Castagneto B, Zai S, Mutti L, et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients. Lung Cancer. 2001 Feb-Mar;31(2–3):303–310. PubMed PMID: 11165411; English.
   PubMed Web of Science ®Google Scholar
• Christmas TI, Manning LS, Garlepp MJ, et al. Effect of interferon-alpha 2a on malignant mesothelioma. J Interferon Res. 1993 Feb;13(1):9–12. PubMed PMID: 8454913; English.
   PubMedGoogle Scholar
• Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer. 1994 Nov 1;74(9):2460–2467. PubMed PMID: 7923001; English.
   PubMed Web of Science ®Google Scholar
• Davidson JA, Musk AW, Wood BR, et al. Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J Immunother. 1998 Sep;21(5):389–398. PubMed PMID: 9789201; English.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018 Mar 23;359(6382):1350–1355. PubMed PMID: 29567705.
   PubMed Web of Science ®Google Scholar
• Camacho LH. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med. 2015 May;4(5):661–672. PubMed PMID: 25619164; PubMed Central PMCID: PMCPMC4430259. English
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. PubMed PMID: 18173375.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2001 May;22(5):265–268. PubMed PMID: 11323285
   PubMed Web of Science ®Google Scholar
• Awad MM, Jones RE, Liu H, et al. Cytotoxic T cells in PD-L1-positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors. Cancer Immunol Res. 2016 Dec;4(12):1038–1048. PubMed PMID: 27856426.
   PubMed Web of Science ®Google Scholar
• Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016 Apr;48(4):407–416. PubMed PMID: 26928227.
   PubMed Web of Science ®Google Scholar
• Cedres S, Ponce-Aix S, Zugazagoitia J, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One. 2015;10(3):e0121071. PubMed PMID: 25774992; PubMed Central PMCID: PMCPMC4361537.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563–567. PubMed PMID: 25428504; PubMed Central PMCID: PMCPMC4836193.
   PubMed Web of Science ®Google Scholar
• Khanna S, Thomas A, Abate-Daga D, et al. Malignant mesothelioma effusions are infiltrated by CD3(+) T cells highly expressing PD-L1 and the PD-L1(+) tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J Thorac Oncol. 2016 Nov;11(11):1993–2005. PubMed PMID: 27544053; PubMed Central PMCID: PMCPMC5075512.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Roden AC, Peikert T, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014 Jul;9(7):1036–1040. PubMed PMID: 24926549; PubMed Central PMCID: PMCPMC4058651.
   PubMed Web of Science ®Google Scholar
• Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018 Oct;13(10):1569–1576. PubMed PMID: 29908324.
   PubMed Web of Science ®Google Scholar
• Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003 Feb 1;170(3):1257–1266. PubMed PMID: 12538684.
   PubMed Web of Science ®Google Scholar
• Combaz-Lair C, Galateau-Salle F, McLeer-Florin A, et al. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Hum Pathol. 2016 Jun;52:9–18. PubMed PMID: 26980049.
   PubMed Web of Science ®Google Scholar
• Inaguma S, Lasota J, Wang Z, et al. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma. Hum Pathol. 2018 Jan;71:1–7. PubMed PMID: 28811252; PubMed Central PMCID: PMCPMC5748003.
   PubMed Web of Science ®Google Scholar
• Tallon de Lara P, Cecconi V, Hiltbrunner S, et al. Gemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients. Clin Cancer Res. 2018 Aug 28. [Epub ahead of print]. PubMed PMID: 30154226. DOI:10.1158/1078-0432.CCR-18-1231.
   PubMed Web of Science ®Google Scholar
• Roncella S, Laurent S, Fontana V, et al. CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor. Cancer Immunol Immunother. 2016 Aug;65(8):909–917. PubMed PMID: 27207606; English.
   PubMed Web of Science ®Google Scholar
• Boyiadzis MM, Kirkwood JM, Marshall JL, et al. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018 May 14;6(1):35. PubMed PMID: 29754585; PubMed Central PMCID: PMCPMC5950135. English.
   PubMedGoogle Scholar
• Arulananda S, Thapa B, Walkiewicz M, et al. Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma. J Thorac Oncol. 2018 Oct;13(10):1588–1594. PubMed PMID: 30056163.
   PubMed Web of Science ®Google Scholar
• Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017(1):1–15. PubMed PMID: 29850653; PubMed Central PMCID: PMCPMC5972025.
   Google Scholar
• Calabro L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013 Oct;14(11):1104–1111. PubMed PMID: 24035405.
   PubMed Web of Science ®Google Scholar
• Calabro L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015 Apr;3(4):301–309. PubMed PMID: 25819643.
   PubMed Web of Science ®Google Scholar
• Maio M, Scherpereel A, Calabro L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017 Sep;18(9):1261–1273. PubMed PMID: 28729154.
   PubMed Web of Science ®Google Scholar
• Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017 May;18(5):623–630. PubMed PMID: 28291584.
   PubMed Web of Science ®Google Scholar
• Desai A, Karrison T, Rose B, et al. Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM). J Clin Oncol. 2018 May 20;36(15):8565. PubMed PMID: WOS:000442916003160; English.
   Google Scholar
• Kindler H, Karrison T, Tan YHC, et al. Phase II trial of pembrolizumab in patients with malignant mesothelioma (MM): interim analysis. J Thorac Oncol. 2017 Jan;12(1):S293–S294. PubMed PMID: WOS:000413055800286; English.
   PubMedGoogle Scholar
• Rivalland G, Kao SCH, Pavlakis N, et al. Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression. J Clin Oncol. 2017 May;20(35):s8514. PubMed PMID: WOS:000411932201092; English.
   Web of Science ®Google Scholar
• Goto Y, Okada M, Kijima T, et al. MA 19.01 A phase II study of nivolumab: a multicenter, open-label, single arm study in malignant pleural mesothelioma (MERIT). J Thorac Oncol. 2017;12(11):S1883.
   Google Scholar
• Hassan R, Thomas A, Nemunaitis JJ, et al. Avelumab in patients with previously treated mesothelioma: updated phase 1b results from the JAVELIN Solid Tumor trial. J Clin Oncol. 2018 Feb 10;36(5):166. PubMed PMID: WOS:000436177700158; English.
   Web of Science ®Google Scholar
• Calabro L, Morra A, Giannarelli D, et al. Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: safety analysis from the phase II NIBIT-MESO-1 study. J Clin Oncol. 2017 May 20;35(15):8558. PubMed PMID: WOS:000411932201135; English.
   Google Scholar
• Zalcman G, Mazieres J, Greillier L, et al. Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial. Ann Onco. 2017 Sep;28:v605–v649. PubMed PMID: WOS:000411324005134; English.
   Web of Science ®Google Scholar
• Nowak AK, Lesterhuis WJ, Hughes BGM, et al. DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma-first results. J Clin Oncol. 2018 May 20;36(15):8503. PubMed PMID: WOS:000442916003101; English.
   Web of Science ®Google Scholar
• Baldo P, Cecco S. Amatuximab and novel agents targeting mesothelin for solid tumors. Onco Targets Ther. 2017;10:5337–5353. PubMed PMID: 29184420; PubMed Central PMCID: PMCPMC5687483. English
   PubMed Web of Science ®Google Scholar
• Hassan R, Kindler HL, Jahan T, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927–5936. PubMed PMID: 25231400; PubMed Central PMCID: PMCPMC4252585. English.
   PubMed Web of Science ®Google Scholar
• Blumenschein GR, Hassan R, Moore KN, et al. Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR). J Clin Oncol. 2016 May 20;34(15):2509. PubMed PMID: WOS:000404665403108; English.
   PubMed Web of Science ®Google Scholar
• Hassan R, Jennens R, Van Meerbeeck J, et al. Randomized phase II study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma. J Thorac Oncol. 2017 Jan;12(1):S1087–S1088. PubMed PMID: WOS:000413055802335; English.
   Web of Science ®Google Scholar
• Maude SL, Teachey DT, Porter DL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015 Jun 25;125(26):4017–4023. PubMed PMID: 25999455; PubMed Central PMCID: PMCPMC4481592.
   PubMed Web of Science ®Google Scholar
• Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood. 2016 Jun 30;127(26):3312–3320. PubMed PMID: 27207800; PubMed Central PMCID: PMCPMC4929923.
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Cherkassky L, Villena-Vargas J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014 Nov 5;6(261):261ra151. PubMed PMID: 25378643; PubMed Central PMCID: PMCPMC4373413.
   PubMed Web of Science ®Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016 Aug 1;126(8):3130–3144. PubMed PMID: 27454297; PubMed Central PMCID: PMCPMC4966328. English.
   PubMed Web of Science ®Google Scholar
• Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med. 2010 Jun 15;181(12):1383–1390. PubMed PMID: 20167848.
   PubMed Web of Science ®Google Scholar
• Cornelissen R, Hegmans JP, Maat AP, et al. Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am J Respir Crit Care Med. 2016 May 1;193(9):1023–1031. PubMed PMID: 26652184; English.
   PubMed Web of Science ®Google Scholar
• Sterman DH, Alley E, Stevenson JP, et al. Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFNalpha combined with chemotherapy. Clin Cancer Res. 2016 Aug 1;22(15):3791–3800. PubMed PMID: 26968202; PubMed Central PMCID: PMCPMC4970934.
   PubMed Web of Science ®Google Scholar
• Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 2010 Jun 1;70(11):4297–4309. PubMed PMID: 20484030.
   PubMed Web of Science ®Google Scholar
• Koski A, Kangasniemi L, Escutenaire S, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther. 2010 Oct;18(10):1874–1884. PubMed PMID: 20664527; PubMed Central PMCID: PMCPMC2951567.
   PubMed Web of Science ®Google Scholar
• Ranki T, Pesonen S, Hemminki A, et al. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer. 2016;4:17. PubMed PMID: 26981247; PubMed Central PMCID: PMCPMC4791966.
   PubMed Web of Science ®Google Scholar
• Danson S, Woll P, Edwards J, et al. 366PDOncolytic herpesvirus therapy for mesothelioma: A phase I/IIa trial of intrapleural administration of HSV1716 (NCT01721018). Ann Oncol. 2017;28(suppl_5):mdx367.001-mdx367.001.
   Google Scholar
• Mukherjee S, Haenel T, Himbeck R, et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther. 2000 May;7(5):663–670. PubMed PMID: 10830713.
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011 Aug 31;477(7362):99–102. PubMed PMID: 21886163.
   PubMed Web of Science ®Google Scholar
• Gauvrit A, Brandler S, Sapede-Peroz C, et al. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res. 2008 Jun 15;68(12):4882–4892. PubMed PMID: 18559536.
   PubMed Web of Science ®Google Scholar
• Li H, Peng KW, Dingli D, et al. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther. 2010 Aug;17(8):550–558. PubMed PMID: 20379224; PubMed Central PMCID: PMCPMC2907639.
   PubMed Web of Science ®Google Scholar
• Eguchi T, Kadota K, Mayor M, et al. Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. Oncotarget. 2017 Sep 29;8(44):77872–77882. PubMed PMID: 29100432; PubMed Central PMCID: PMCPMC5652821.
   PubMedGoogle Scholar
• Hassan R, Alley EW, Kindler HL, et al. CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM). J Clin Oncol. 2016 May 20;34(15):8558. PubMed PMID: WOS:000404711506032; English.
   Web of Science ®Google Scholar
• Krug LM, Dao T, Brown AB, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother. 2010 Oct;59(10):1467–1479. PubMed PMID: 20532500; PubMed Central PMCID: PMCPMC4004362. English.
   PubMed Web of Science ®Google Scholar
• Zauderer MG, Tsao AS, Dao T, et al. A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma. Clin Cancer Res. 2017 Dec 15;23(24):7483–7489. PubMed PMID: 28972039; PubMed Central PMCID: PMCPMC5732877. English.
   PubMed Web of Science ®Google Scholar
• Elsamadicy AA, Chongsathidkiet P, Desai R, et al. Prospect of rindopepimut in the treatment of glioblastoma. Expert Opin Biol Ther. 2017 Apr;17(4):507–513. PubMed PMID: 28274144; PubMed Central PMCID: PMCPMC5787389.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004 Sep;10(9):909–915. PubMed PMID: 15340416; PubMed Central PMCID: PMCPMC1435696
   PubMed Web of Science ®Google Scholar
• Vansteenkiste JF, Cho BC, Vanakesa T, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016 Jun;17(6):822–835. PubMed PMID: WOS:000377066400066; English.
   PubMed Web of Science ®Google Scholar
• Carreno BM, Magrini V, Becker-Hapak M, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015 May 15;348(6236):803–808. PubMed PMID: 25837513; PubMed Central PMCID: PMCPMC4549796.
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014 Dec 4;371(23):2189–2199. PubMed PMID: 25409260; PubMed Central PMCID: PMCPMC4315319. English.
   PubMed Web of Science ®Google Scholar
• Wick DA, Webb JR, Nielsen JS, et al. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res. 2014 Mar 1;20(5):1125–1134. PubMed PMID: 24323902; English.
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014 May 9;344(6184):641–645. PubMed PMID: 24812403; English.
   PubMed Web of Science ®Google Scholar
• Rajasagi M, Shukla SA, Fritsch EF, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014 Jul 17;124(3):453–462. PubMed PMID: 24891321; PubMed Central PMCID: PMCPMC4102716. English.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015 Apr 3;348(6230):124–128. PubMed PMID: 25765070; PubMed Central PMCID: PMCPMC4993154. English.
   PubMed Web of Science ®Google Scholar
• Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014 Nov 27;515(7528):577–581. PubMed PMID: 25428507; PubMed Central PMCID: PMCPMC4279952.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun;19(6):747–752. PubMed PMID: 23644516; PubMed Central PMCID: PMCPMC3757932.
   PubMed Web of Science ®Google Scholar
• van Rooij N, van Buuren MM, Philips D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013 Nov 10;31(32):e439–e442. PubMed PMID: 24043743; PubMed Central PMCID: PMCPMC3836220. English.
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015 Oct 9;350(6257):207–211. PubMed PMID: 26359337; PubMed Central PMCID: PMCPMC5054517.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018 May 31;378(22):2093–2104. PubMed PMID: 29658845.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 Jul 28;357(6349):409–413. PubMed PMID: 28596308; PubMed Central PMCID: PMCPMC5576142.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016 Mar 25;351(6280):1463–1469. PubMed PMID: 26940869; PubMed Central PMCID: PMCPMC4984254.
   PubMed Web of Science ®Google Scholar
• Benedetti S, Nuvoli B, Catalani S, et al. Reactive oxygen species a double-edged sword for mesothelioma. Oncotarget. 2015 Jul 10;6(19):16848–16865. PubMed PMID: 26078352; PubMed Central PMCID: PMCPMC4627278.
   PubMed Web of Science ®Google Scholar
• Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011 Jun 5;43(7):668–672. PubMed PMID: 21642991; PubMed Central PMCID: PMCPMC4643098.
   PubMed Web of Science ®Google Scholar
• Guo G, Chmielecki J, Goparaju C, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015 Jan 15;75(2):264–269. PubMed PMID: 25488749.
   PubMed Web of Science ®Google Scholar
• Lo Iacono M, Monica V, Righi L, et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol. 2015 Mar;10(3):492–499. PubMed PMID: 25514803.
   PubMed Web of Science ®Google Scholar
• Lee HS, Jang HJ, Choi JM, et al. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight. 2018 Apr 5;3(7). PubMed PMID: 29618661; PubMed Central PMCID: PMCPMC5928857. DOI:10.1172/jci.insight.98575.
   Web of Science ®Google Scholar
• Lai J, Zhou Z, Tang XJ, et al. A tumor-specific neo-antigen caused by a frameshift mutation in BAP1 is a potential personalized biomarker in malignant peritoneal mesothelioma. Int J Mol Sci. 2016 May 14;17(5). PubMed PMID: 27187383; PubMed Central PMCID: PMCPMC4881561. English. DOI:10.3390/ijms17050739.
   Web of Science ®Google Scholar
• Creaney J, Ma S, Sneddon SA, et al. Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. Oncoimmunology. 2015 Jul;4(7):e1011492. PubMed PMID: 26140232; PubMed Central PMCID: PMCPMC4485777. English.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 Jul 13;547(7662):217–221. PubMed PMID: 28678778; PubMed Central PMCID: PMCPMC5577644.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017 Jul 13;547(7662):222–226. PubMed PMID: 28678784; English.
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Kaluza KM, Freeman GJ, et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013 Jun 15;73(12):3591–3603. PubMed PMID: 23633484; PubMed Central PMCID: PMCPMC3686913. English.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252–264. PubMed PMID: 22437870; PubMed Central PMCID: PMCPMC4856023. English.
   PubMed Web of Science ®Google Scholar
• Yadav M, Jhunjhunwala S, Phung QT, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014 Nov 27;515(7528):572–576. PubMed PMID: 25428506; English.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Vormehr M, van de Roemer N, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015 Apr 30;520(7549):692–696. PubMed PMID: 25901682; PubMed Central PMCID: PMCPMC4838069.
   PubMed Web of Science ®Google Scholar